Antisense Pharma with new focus
The pharmaceutical company located in BioPark Regensburg has completed the clinical phase III study for the treatment of brain tumours (anaplastic astrocytoma), as in the foreseen time insufficient suitable patients were able to be recruited. Trabedersen is an anti-TGF-β2 Antisense active substance, which in a series of studies presented promising evidence to prolong survival for several indications in the treatment of cancer. The commencement of a phase II study for second-line treatment of pancreatic carcinoma is planned for 2012. Furthermore in the future Antisense Pharma will pursue the development of Trabedersen as a first-line treatment for patients with glioblastoma (malignant brain tumour) and pancreatic carcinoma in combination with standard therapy.
For more information see: